about
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsFrom kinetics and cellular cooperations to cancer immunotherapiesVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationFCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions.A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerClinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Computational systems biology approaches to anti-angiogenic cancer therapeutics.A distinct mechanism of vascular lumen formation in Xenopus requires EGFL7Angiogenesis QTL on Mouse Chromosome 8 Colocalizes with Differential β-Defensin Expression.Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Interleukin-8: A potent promoter of angiogenesis in gastric cancer.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.Plasma Fibrinogen Correlates with Metastasis and is Associated with Prognosis in Human Nasopharyngeal Carcinoma.Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancerCellular and molecular mechanisms underlying blood vessel lumen formation.Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions.MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyCLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis.Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor.Ten years of anti-vascular endothelial growth factor therapy.VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways.Dual role of autophagy in hallmarks of cancer.The Role of Wnt Signalling in Angiogenesis.Unveiling a VEGF-mimetic peptide sequence in the IQGAP1 protein.Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade.A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations.Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
P2860
Q26749011-C6BE5216-39EE-4FC4-924B-ACC55F5628CBQ26750783-1685D31B-1708-4220-9217-AE625976E162Q26781833-5A2B0C6C-92AE-42BD-A612-7098037F1D20Q33416596-5BEC230E-DB7F-4209-BBFD-4A71083D3F27Q34081464-E4EA4EA5-A24A-4C28-9E49-CCA26911D0C6Q34657338-4EDA3D5E-61B5-41AB-A8AA-2B3891E5593BQ34943606-C7DC738E-65A6-45B6-BF9D-6F0636106F91Q35108084-545D817C-75D6-4B2C-A575-AEEAE50EC38BQ35112500-995F39D9-FA4B-49CA-9CE9-3839AF15A340Q35195337-01A407E7-ED78-491E-BC27-7F74E06BE420Q35742534-70446DD8-6F17-43ED-8496-E1D16A21BFD9Q35895339-42C309BB-EB5B-47C9-A4A2-6EE95FA5A475Q36153108-D5AFAD3E-2A72-4977-9C2C-24FC6C5E678AQ36228258-EF281541-7AE4-49F8-8E06-5E81CE5C0F12Q36428702-AA51A3AA-6C07-4C20-8E3A-8B64C7FAEC56Q36524643-4DED5C56-F5F5-4121-B870-149B3958BCC4Q36854062-169162DE-966D-48FA-A891-756C466A2E68Q37141599-1D690CD6-2C23-4B8F-B3FC-1D2177BFABB8Q37577621-18867FF1-45BE-42D5-93D0-3700F45A8C85Q37675965-1A883643-AFBB-49A1-8B94-E989C919F11AQ37696220-C6C09F40-A125-4FF0-9C59-B209DFBEDE45Q38125964-EFA6E741-8FBE-4F62-B761-A1F8DA5007CDQ38170082-5295B593-3C5C-4B26-A93C-CD4E94412E12Q38213539-8ACC3DF8-0D9D-4670-AA50-27931995F1F6Q38718622-4B43662A-AAA1-40E5-9A8B-7C3347090E7DQ38845254-CE161185-6CF9-4998-81AF-9EDC12704B27Q38849027-4D2DED0A-8CB5-44D3-8B20-5A3CD1474403Q39390383-4916F7FD-7404-4C03-A283-07EC285DB977Q39406918-DA9A630C-A73E-466F-B0BF-8691E20E3757Q41439263-2856AB3C-1404-47C5-BC2E-B2310923DD39Q41629417-4ED4C510-E85B-4CCD-98E1-90D7A885694DQ42431654-E19392B8-FAF3-45A0-B7B6-2593D4734FA1Q46407140-436C172A-38DD-4D34-8748-B60F06A31A5CQ47100851-98915BA7-5CDD-438B-A788-4B8138D506B8Q47236671-2FFFDAA1-3F58-466F-9C52-B515229F4101Q47553825-2BC10CAA-46FE-4793-A8FE-871AFB6BDF12Q48162548-E93E0F14-1640-493E-8884-376477743E3BQ52763518-2403F3E1-54F4-4D4B-BD98-28A4992FE85AQ53566121-F7CF4317-CB59-4367-869C-E501A09ADB7CQ54268778-A9A81372-1297-4AC7-A057-4616F2AD3C77
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Anti-VEGF therapies in the clinic
@ast
Anti-VEGF therapies in the clinic
@en
type
label
Anti-VEGF therapies in the clinic
@ast
Anti-VEGF therapies in the clinic
@en
prefLabel
Anti-VEGF therapies in the clinic
@ast
Anti-VEGF therapies in the clinic
@en
P2860
P1476
Anti-VEGF therapies in the clinic
@en
P2093
Herbert I Hurwitz
Kellen L Meadows
P2860
P356
10.1101/CSHPERSPECT.A006577
P577
2012-10-01T00:00:00Z